Rajan Gulati

Glenmark Life Sciences IPO: Information analysis

This manufacturer of active pharmaceutical ingredients aims to raise Rs 1,514 crore through an initial public offering. Should you invest in it?

Tatva Chintan Pharma: IPO analysis

This speciality-chemical company is looking to raise Rs 500 crore through an IPO. Should you bid for its shares?

Metrics for new-age companies

Apart from traditional metrics, such as profits, cash flows and debt, keep an eye on these when you analyse new-age businesses

Clean Science and Technology IPO: Information analysis

This speciality-chemical player aims to raise Rs 1,546 crore through an IPO. Should you bid for its shares?

Which are better: dividend payers or non-dividend-payers?

Are non-dividend-paying companies better in terms of returns and fundamental performance than dividend payers? Find out here.

The CASA saga

Current and savings accounts are a cheap source of funds for banks. Here are the leaders and laggards as per this metric.

Delving into depreciation

Should you ignore depreciation while analysing companies?

India Pesticides IPO: Information analysis

This agro-chemical manufacturer aims to raise Rs 800 crore through an initial public offering. Find out if you should invest in its shares.

Sona BLW IPO: Information analysis

This auto-component maker is raising Rs 5,550 crore through an IPO. Should you bid for its shares? Read the full analysis to find out.

How to invest in cyclicals

Profiting from cyclicals requires a combination of vigilance, patience and enterprise. Of course, you can take the indirect route as well.